₹1,147.80
−2.28%NSE close, 16 Nov 2026
+39.47%
Senores Pharmaceuticals is a small cap company in the Healthcare sector, listed on NSE under the symbol SENORES. At ₹1,147.80 a share, the market values the whole company at ₹5,286 crore.
In FY26, it reported sales of ₹633 crore and a net profit of ₹122 crore, an operating margin of 26.6%.
The market values the company at 38.2 times its profit over the last twelve months and 5.27 times its book value; its return on equity is 13.8% and its borrowings are 0.39 times its equity.
Promoters hold 45.82% of the shares, and have pledged 2.8% of their holding. Foreign institutions hold 6.01%, and domestic institutions, mutual funds among them, 10.84%.
Over the past year the share price has risen 42.6%, and it is 28.2% below its 52-week high.
Companies of a similar size in the same sector include Aarti Pharmalabs, Healthcare Global Enterprises, Thyrocare Technologies and Suven Life Sciences.
₹ crore. Consolidated figures.
The same sector (Healthcare), nearest in size.
| Company | Price | Market cap | P/E | ROE | Sales growth | 1Y |
|---|---|---|---|---|---|---|
| Senores Pharmaceuticals | ₹1,147.80 | ₹5,286 cr | 38.2 | 13.8% | +18.90% | +42.61% |
| Aarti Pharmalabs | ₹986.75 | ₹8,948 cr | 35.4 | 11.2% | +45.90% | +16.93% |
| Healthcare Global Enterprises | ₹568.20 | ₹8,483 cr | 750.7 | 0.8% | +13.10% | −24.77% |
| Thyrocare Technologies | ₹509.65 | ₹8,112 cr | 56.3 | 26.1% | +25.10% | +15.46% |
| Suven Life Sciences | ₹268.90 | ₹7,598 cr | n/a |
Transcript
Link of Recording
| Sales | 103 | 114 | 138 | 162 | 175 | 175 | 180 | 192 |
|---|---|---|---|---|---|---|---|---|
| Expenses | 77.3 | 94.8 | 104 | 112 | 121 | 128 | 126 | 135 |
| Operating profit | 25.7 | 19.4 | 34.2 | 49.5 | 54.0 | 47.5 | 53.8 | 57.7 |
| Operating margin | 24.9% | 17.0% | 24.8% | 30.6% | 30.9% | 27.1% | 29.8% | 30.0% |
| Other income | 5.2 | 11.8 | 3.4 | 5.4 | 3.8 | 17.7 | 2.8 | 8.9 |
| Interest | 6.2 | 5.3 | 5.0 | 6.2 | 5.3 | 8.5 | 7.2 | 8.8 |
| Depreciation | 4.2 | 5.2 | 6.0 | 8.1 | 7.9 | 9.3 | 9.9 | 10.3 |
| Profit before tax | 20.5 | 20.7 | 26.5 | 40.6 | 44.6 | 47.4 | 39.5 | 47.6 |
| Tax | 4.1 | 2.7 | 5.3 | 10.5 | 11.0 | 10.7 | 9.0 | 11.0 |
| Net profit | 17.2 | 18.0 | 19.7 | 32.4 | 31.7 | 36.7 | 30.7 | 39.5 |
| EPS (₹) | 5.04 | 3.81 | 4.60 | 6.54 | 7.29 | 7.96 | 6.61 | 8.85 |
₹ crore, financial years to March.
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|
| From operations | −45.9 | 62.1 | 29.2 |
| From investing | −429 | −121 | −112 |
| From financing | 573 | −1.3 | 55.4 |
| Spent on fixed assets | −158 | −240 | −137 |
| Free cash flow | −203 | −178 | −107 |
Margins, returns, debt, tax and cash.
| Line | FY25 | FY26 |
|---|---|---|
| Net margin | 14.6% | 19.2% |
| Operating margin | 22.5% | 26.6% |
| Return on equity | 7.4% | 13.0% |
| Return on capital employed | 8.4% | 14.6% |
| Return on assets | 4.8% | 7.6% |
| Debt to equity | 0.39 | 0.35 |
| Interest coverage | 4.30 | 7.40 |
| Debt to assets | 0.25 | 0.20 |
| Current ratio | 3.00 | 1.92 |
| Quick ratio | 2.77 | 1.71 |
| Cash ratio | 0.44 | 0.11 |
| Asset turnover | 0.32 | 0.39 |
| Fixed asset turnover | 2.00 | 1.91 |
| Inventory turnover | 3.20 | 2.80 |
| Receivables turnover | 3.20 | 1.90 |
| Gross margin | 54.6% | 60.2% |
| Cash from operations to profit | -79.0% | 51.0% |
| Effective tax rate | 17.3% | 23.6% |
| -84.2% |
| +30.40% |
| +39.45% |
| Nephrocare Health Services | ₹642.00 | ₹6,456 cr | 50.4 | 10.8% | n/a | n/a |
|---|
| Sun Pharma Advanced Research Company | ₹195.84 | ₹6,355 cr | 3.9 | 113.4% | +282.10% | +45.52% |
|---|
| Supriya Lifescience | ₹622.30 | ₹5,008 cr | 28.3 | 14.3% | +3.20% | −20.15% |
|---|
| Advanced Enzyme Technologies | ₹280.85 | ₹3,122 cr | 18.3 | 10.3% | +16.20% | −9.69% |
|---|
Monitoring Agency report for the quarter ended September 30, 2026
Change in Auditors of the company.
A Media release dated October 29, 2026
Capacity expansion
Outcome of board Meeting held on October 29, 2026
Schedule of meet
Schedule of meet
Notice of Postal Ballot
Re-appointment of Mr. Chetan Bipinchandra Shah as the Whole Time Director of the Company w.e.f. November 10, 2026.
Re-appointment of Mr. Swapnil Jatinbhai Shah as the Managing Director of the company w.e.f. October 15, 2026.